B-RAF with PLX4032
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
<scene name='B-RAF_with_PLX4032/Plx_4032_only/1'>PLX 4032</scene><br> | <scene name='B-RAF_with_PLX4032/Plx_4032_only/1'>PLX 4032</scene><br> | ||
| - | <scene name='B-RAF_with_PLX4032/Atp/1'>ATP</scene> | + | <scene name='B-RAF_with_PLX4032/Atp/1'>ATP</scene><br> |
<scene name='B-RAF_with_PLX4032/Wild-type_b-raf/1'>Wild-Type B-RAF</scene> <br> | <scene name='B-RAF_with_PLX4032/Wild-type_b-raf/1'>Wild-Type B-RAF</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/Mutated_v600e/1'>V600E Mutation</scene> <br> | <scene name='B-RAF_with_PLX4032/Mutated_v600e/1'>V600E Mutation</scene> <br> | ||
Revision as of 02:31, 5 October 2010
B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
|
|
